PRECEPTORSHIP PROGRAMME

Breast Cancer
Multidisciplinary management, standards of care, therapeutic targets and future perspectives

CAPE TOWN
SOUTH AFRICA

13-14 FEBRUARY 2020

Co-Chairs
Fatima Cardoso, Portugal
Georgia Demetriou, South Africa
ESMO PRECEPTORSHIP PROGRAMME
BREAST CANCER
Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Cape Town, South Africa
13-14 February 2020

CO-CHAIRS: Fatima Cardoso, Portugal
Georgia Demetriou, South Africa

SPEAKERS: Ines Buccimazza, South Africa
Devan Moodley, South Africa
Magali Lacroix-Triki, France
Peter Schoub, South Africa
Alicia Sherriff, South Africa
Verna Vanderpuye, Ghana
Daniel Vorobiof, Israel/South Africa

LEARNING OBJECTIVES
• To learn about screening, diagnosis and staging of breast cancer
• To learn about the biology of breast cancer and its implications in the management of this disease
• To learn about the standard of care management of early, locally advanced and metastatic breast cancer in
  surgery, radiation therapy and systemic therapy
• To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION
The programme of this event has been accredited with 9 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification
guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the
necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS
ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
### Thursday, 13 February 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:35</td>
<td>Opening and welcome</td>
<td></td>
</tr>
</tbody>
</table>
| 08:35-10:25 | **MODULE 1**  
Pathology  
25’ New breast cancer classification: traditional pathology and molecular subtypes  
20’ Inflammatory Breast Cancer: definition and biology  
25’ Prognostic and predictive markers for breast cancer management  
10’ Discussion | Magali Lacroix-Triki, FR  
Magali Lacroix-Triki, FR  
Magali Lacroix-Triki, FR  
All |
| 10:25-12:05 | **MODULE 2**  
Local-Regional Treatments  
30’ Principles of breast surgery/oncplastic surgery  
30’ Principles of breast radiation therapy  
10’ Discussion | Ines Buccimazza, ZA  
Alicia Sherriff, ZA  
All |
| 12:05-12:15 | Coffee break                                                         |                                      |
| 12:05-15:20 | **MODULE 3**  
ER+ (Luminal-like) Breast Cancer  
25’ Endocrine-based therapy for advanced breast cancer  
25’ When CT is needed for ER+/HER2 negative advanced breast cancer | Fatima Cardoso, PT  
Verna Vanderpuye, GH |
| 12:55-14:00 | Lunch                                                                |                                      |
| 15:20-16:20 | **MODULE 4**  
Imaging  
25’ Screening  
25’ Imaging (diagnosis and staging)  
10’ Discussion | Peter Schoub, ZA  
Peter Schoub, ZA  
All |
| 16:20-16:45 | Coffee break                                                         |                                      |
| 16:45-18:15 | **MODULE 5**  
HER2+ Breast Cancer  
30’ (Neo-) Adjuvant systemic therapy  
30’ Systemic therapy for HER2+ advanced breast cancer  
10’ Discussion  
20’ Clinical case presentations from the audience (2x10’) | Fatima Cardoso, PT  
Fatima Cardoso, PT  
All  
All |
| 20:00      | Dinner                                                               |                                      |

**Note:** Local-regional and systemic treatment of LABC and IBC will be incorporated in all relevant talks.
**Friday, 14 February 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Module</th>
<th>Content</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:50</td>
<td>MODULE 6</td>
<td>80’</td>
<td></td>
</tr>
<tr>
<td>25’</td>
<td>(Neo-) Adjuvant systemic therapy</td>
<td></td>
<td>Georgia Demetriou, ZA</td>
</tr>
<tr>
<td>25’</td>
<td>Systemic therapy for TN advanced breast cancer</td>
<td></td>
<td>Georgia Demetriou, ZA</td>
</tr>
<tr>
<td>10’</td>
<td>Discussion</td>
<td></td>
<td>All</td>
</tr>
<tr>
<td>20’</td>
<td>Clinical case presentations from the audience (2x10’)</td>
<td></td>
<td>All</td>
</tr>
<tr>
<td>09:50-10:10</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10-10:35</td>
<td>MODULE 7</td>
<td>25’</td>
<td></td>
</tr>
<tr>
<td>25’</td>
<td>Breast Cancer and pregnancy</td>
<td></td>
<td>Fatima Cardoso, PT</td>
</tr>
<tr>
<td>10:35-10:40</td>
<td>Closing remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5’</td>
<td>Closing remarks</td>
<td></td>
<td>Fatima Cardoso, PT</td>
</tr>
</tbody>
</table>

**Note:** Each 10 minute slot for clinical case discussion includes 5’ case presentation and 5’ Q&A/panel discussion.